| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nursing Homes | 16 | 2016 | 41 | 5.040 |
Why?
|
| Longevity | 22 | 2023 | 143 | 3.980 |
Why?
|
| Geriatrics | 11 | 2022 | 51 | 3.610 |
Why?
|
| Aging | 34 | 2023 | 639 | 3.290 |
Why?
|
| Aged | 144 | 2023 | 6448 | 3.060 |
Why?
|
| Hawaii | 87 | 2024 | 1878 | 2.860 |
Why?
|
| Aged, 80 and over | 93 | 2023 | 2333 | 2.770 |
Why?
|
| Hypertension | 19 | 2023 | 770 | 2.740 |
Why?
|
| Cognition Disorders | 26 | 2022 | 233 | 2.590 |
Why?
|
| Dementia | 31 | 2022 | 133 | 2.570 |
Why?
|
| Humans | 214 | 2024 | 34853 | 2.170 |
Why?
|
| Polypharmacy | 5 | 2014 | 27 | 2.140 |
Why?
|
| Risk Factors | 78 | 2023 | 3414 | 2.130 |
Why?
|
| Male | 158 | 2023 | 18870 | 2.040 |
Why?
|
| Stroke | 11 | 2023 | 274 | 1.970 |
Why?
|
| Alzheimer Disease | 25 | 2023 | 881 | 1.920 |
Why?
|
| Education, Distance | 3 | 2024 | 40 | 1.870 |
Why?
|
| Japan | 51 | 2022 | 296 | 1.820 |
Why?
|
| Coronary Disease | 17 | 2020 | 113 | 1.790 |
Why?
|
| Cognition | 12 | 2022 | 373 | 1.750 |
Why?
|
| Health Personnel | 3 | 2019 | 200 | 1.590 |
Why?
|
| Curriculum | 7 | 2018 | 237 | 1.520 |
Why?
|
| Parkinson Disease | 12 | 2023 | 167 | 1.480 |
Why?
|
| Telemedicine | 2 | 2023 | 163 | 1.470 |
Why?
|
| Prospective Studies | 41 | 2023 | 1353 | 1.470 |
Why?
|
| Education, Medical, Graduate | 4 | 2014 | 53 | 1.460 |
Why?
|
| Clinical Competence | 8 | 2018 | 124 | 1.440 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 105 | 1.400 |
Why?
|
| Vitamin D | 6 | 2016 | 176 | 1.290 |
Why?
|
| Dementia, Vascular | 7 | 2023 | 34 | 1.280 |
Why?
|
| Cooperative Behavior | 2 | 2019 | 205 | 1.230 |
Why?
|
| Interprofessional Relations | 5 | 2024 | 48 | 1.200 |
Why?
|
| Genotype | 17 | 2023 | 641 | 1.190 |
Why?
|
| Middle Aged | 82 | 2022 | 9642 | 1.190 |
Why?
|
| Longitudinal Studies | 28 | 2023 | 841 | 1.180 |
Why?
|
| Polymorphism, Single Nucleotide | 16 | 2023 | 638 | 1.170 |
Why?
|
| Patient Care Team | 2 | 2018 | 44 | 1.140 |
Why?
|
| Pharmacy | 2 | 2024 | 26 | 1.100 |
Why?
|
| Proteinuria | 3 | 2015 | 48 | 1.090 |
Why?
|
| Incidence | 29 | 2023 | 882 | 1.080 |
Why?
|
| Geriatric Assessment | 11 | 2016 | 52 | 1.060 |
Why?
|
| Coronary Artery Disease | 11 | 2017 | 147 | 1.010 |
Why?
|
| Physician-Patient Relations | 3 | 2017 | 118 | 0.980 |
Why?
|
| Brain | 19 | 2019 | 1268 | 0.980 |
Why?
|
| Pesticides | 4 | 2019 | 44 | 0.970 |
Why?
|
| Cerebral Hemorrhage | 4 | 2022 | 103 | 0.950 |
Why?
|
| Risk Assessment | 21 | 2020 | 727 | 0.940 |
Why?
|
| Physician Executives | 2 | 2013 | 4 | 0.920 |
Why?
|
| Cohort Studies | 33 | 2020 | 1422 | 0.900 |
Why?
|
| Palliative Care | 4 | 2020 | 52 | 0.880 |
Why?
|
| Students, Nursing | 1 | 2023 | 31 | 0.880 |
Why?
|
| Homes for the Aged | 2 | 2012 | 14 | 0.860 |
Why?
|
| Needs Assessment | 3 | 2019 | 159 | 0.850 |
Why?
|
| Body Mass Index | 17 | 2021 | 775 | 0.840 |
Why?
|
| Vitamin D Deficiency | 4 | 2016 | 94 | 0.810 |
Why?
|
| Age Factors | 24 | 2020 | 1007 | 0.770 |
Why?
|
| Occupational Exposure | 2 | 2019 | 67 | 0.770 |
Why?
|
| Sleep Apnea, Central | 1 | 2020 | 4 | 0.760 |
Why?
|
| Atrial Flutter | 1 | 2020 | 7 | 0.760 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2020 | 6 | 0.760 |
Why?
|
| Occupational Health | 2 | 2019 | 19 | 0.750 |
Why?
|
| Fatty Acids, Omega-3 | 5 | 2022 | 36 | 0.750 |
Why?
|
| Female | 69 | 2022 | 19873 | 0.740 |
Why?
|
| Attitude of Health Personnel | 5 | 2020 | 186 | 0.740 |
Why?
|
| Asia | 10 | 2023 | 74 | 0.740 |
Why?
|
| Agricultural Workers' Diseases | 1 | 2019 | 2 | 0.730 |
Why?
|
| Lewy Bodies | 11 | 2019 | 28 | 0.730 |
Why?
|
| Cross-Sectional Studies | 29 | 2021 | 2561 | 0.720 |
Why?
|
| Weight Loss | 6 | 2013 | 124 | 0.720 |
Why?
|
| Aortic Diseases | 5 | 2019 | 26 | 0.690 |
Why?
|
| Fellowships and Scholarships | 4 | 2014 | 26 | 0.670 |
Why?
|
| Educational Measurement | 4 | 2014 | 80 | 0.660 |
Why?
|
| Leukocyte Count | 2 | 2015 | 74 | 0.650 |
Why?
|
| Humanism | 1 | 2017 | 2 | 0.630 |
Why?
|
| Follow-Up Studies | 24 | 2019 | 964 | 0.630 |
Why?
|
| Sarcopenia | 1 | 2017 | 9 | 0.630 |
Why?
|
| Community Health Services | 1 | 2019 | 175 | 0.630 |
Why?
|
| Life Style | 10 | 2021 | 288 | 0.610 |
Why?
|
| Anthropometry | 1 | 2017 | 91 | 0.610 |
Why?
|
| Blood Pressure | 9 | 2020 | 613 | 0.600 |
Why?
|
| Internship and Residency | 5 | 2014 | 121 | 0.600 |
Why?
|
| Electrocardiography | 4 | 2023 | 154 | 0.600 |
Why?
|
| Alleles | 6 | 2023 | 284 | 0.590 |
Why?
|
| Depression | 7 | 2022 | 664 | 0.580 |
Why?
|
| Dietary Supplements | 4 | 2015 | 196 | 0.580 |
Why?
|
| United States | 30 | 2020 | 3894 | 0.550 |
Why?
|
| Lewy Body Disease | 4 | 2019 | 14 | 0.550 |
Why?
|
| Estrogens, Conjugated (USP) | 6 | 2020 | 11 | 0.540 |
Why?
|
| Obesity | 6 | 2018 | 965 | 0.540 |
Why?
|
| Neuropsychological Tests | 12 | 2022 | 255 | 0.540 |
Why?
|
| Cholesterol | 8 | 2020 | 194 | 0.520 |
Why?
|
| Proportional Hazards Models | 18 | 2014 | 423 | 0.520 |
Why?
|
| Granulocytes | 1 | 2014 | 28 | 0.520 |
Why?
|
| Alcohol Drinking | 6 | 2021 | 490 | 0.510 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2014 | 75 | 0.510 |
Why?
|
| Diet | 7 | 2022 | 747 | 0.500 |
Why?
|
| Calcium, Dietary | 2 | 2015 | 83 | 0.500 |
Why?
|
| Communication | 2 | 2017 | 170 | 0.500 |
Why?
|
| Prevalence | 20 | 2020 | 1425 | 0.490 |
Why?
|
| Terminal Care | 2 | 2016 | 47 | 0.490 |
Why?
|
| Adult | 39 | 2022 | 11034 | 0.490 |
Why?
|
| Neutrophils | 1 | 2014 | 124 | 0.490 |
Why?
|
| Long-Term Care | 5 | 2013 | 43 | 0.490 |
Why?
|
| Role Playing | 1 | 2013 | 2 | 0.490 |
Why?
|
| Schools, Medical | 2 | 2018 | 192 | 0.490 |
Why?
|
| Lipoproteins, HDL | 3 | 2022 | 43 | 0.460 |
Why?
|
| Nursing Staff | 1 | 2012 | 8 | 0.450 |
Why?
|
| Retrospective Studies | 14 | 2023 | 1961 | 0.440 |
Why?
|
| Family | 2 | 2013 | 162 | 0.440 |
Why?
|
| Professional-Family Relations | 2 | 2011 | 8 | 0.430 |
Why?
|
| Neurofibrillary Tangles | 8 | 2016 | 112 | 0.420 |
Why?
|
| Internal Medicine | 3 | 2008 | 25 | 0.420 |
Why?
|
| Hospitals | 2 | 2010 | 86 | 0.410 |
Why?
|
| Attitude to Death | 2 | 2020 | 20 | 0.410 |
Why?
|
| Leukoencephalopathies | 1 | 2011 | 3 | 0.410 |
Why?
|
| Cardiovascular Diseases | 6 | 2021 | 628 | 0.410 |
Why?
|
| Postmenopause | 8 | 2022 | 125 | 0.410 |
Why?
|
| Urinary Calculi | 1 | 2011 | 2 | 0.410 |
Why?
|
| Hospitalization | 5 | 2015 | 370 | 0.410 |
Why?
|
| Hotlines | 1 | 2011 | 14 | 0.410 |
Why?
|
| Caregivers | 1 | 2013 | 167 | 0.390 |
Why?
|
| Death | 4 | 2015 | 8 | 0.390 |
Why?
|
| Leadership | 1 | 2011 | 63 | 0.390 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 74 | 0.390 |
Why?
|
| Time Factors | 14 | 2016 | 1681 | 0.390 |
Why?
|
| Smoking | 13 | 2022 | 903 | 0.380 |
Why?
|
| Physician's Role | 1 | 2010 | 34 | 0.380 |
Why?
|
| Logistic Models | 11 | 2020 | 894 | 0.380 |
Why?
|
| Calcinosis | 4 | 2016 | 56 | 0.380 |
Why?
|
| Acculturation | 1 | 2012 | 172 | 0.380 |
Why?
|
| Health Status | 5 | 2022 | 356 | 0.370 |
Why?
|
| Cause of Death | 4 | 2017 | 154 | 0.370 |
Why?
|
| Case-Control Studies | 13 | 2023 | 1056 | 0.370 |
Why?
|
| Calcium Carbonate | 3 | 2015 | 8 | 0.370 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 254 | 0.360 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2016 | 206 | 0.360 |
Why?
|
| Eicosapentaenoic Acid | 3 | 2022 | 14 | 0.350 |
Why?
|
| Docosahexaenoic Acids | 3 | 2022 | 18 | 0.350 |
Why?
|
| Comorbidity | 10 | 2016 | 606 | 0.350 |
Why?
|
| Sex Factors | 10 | 2020 | 859 | 0.350 |
Why?
|
| Death Certificates | 1 | 2009 | 12 | 0.350 |
Why?
|
| Disease Progression | 11 | 2020 | 580 | 0.340 |
Why?
|
| Mortality | 4 | 2016 | 150 | 0.340 |
Why?
|
| Home Care Services | 1 | 2009 | 29 | 0.340 |
Why?
|
| Blood Pressure Determination | 4 | 2020 | 53 | 0.340 |
Why?
|
| Forkhead Transcription Factors | 4 | 2014 | 74 | 0.330 |
Why?
|
| Genetic Variation | 5 | 2021 | 328 | 0.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2020 | 592 | 0.320 |
Why?
|
| Multivariate Analysis | 9 | 2018 | 570 | 0.310 |
Why?
|
| Gambling | 1 | 2006 | 15 | 0.300 |
Why?
|
| Disability Evaluation | 4 | 2015 | 56 | 0.290 |
Why?
|
| Women's Health | 7 | 2022 | 135 | 0.290 |
Why?
|
| Adiposity | 2 | 2018 | 145 | 0.290 |
Why?
|
| Medroxyprogesterone Acetate | 4 | 2020 | 11 | 0.290 |
Why?
|
| Substantia Nigra | 3 | 2015 | 41 | 0.290 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2015 | 44 | 0.290 |
Why?
|
| Antihypertensive Agents | 5 | 2020 | 284 | 0.280 |
Why?
|
| Hydrocarbons, Chlorinated | 2 | 2018 | 17 | 0.280 |
Why?
|
| Cholesterol, HDL | 4 | 2018 | 87 | 0.280 |
Why?
|
| Diabetes Mellitus | 6 | 2016 | 465 | 0.280 |
Why?
|
| Motor Activity | 5 | 2013 | 393 | 0.270 |
Why?
|
| Advance Care Planning | 2 | 2016 | 19 | 0.270 |
Why?
|
| Activities of Daily Living | 4 | 2013 | 104 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2020 | 528 | 0.270 |
Why?
|
| Predictive Value of Tests | 8 | 2015 | 424 | 0.260 |
Why?
|
| Educational Status | 4 | 2023 | 295 | 0.260 |
Why?
|
| Apolipoproteins E | 2 | 2022 | 129 | 0.250 |
Why?
|
| Odds Ratio | 7 | 2015 | 517 | 0.250 |
Why?
|
| Republic of Korea | 8 | 2018 | 103 | 0.250 |
Why?
|
| Skilled Nursing Facilities | 1 | 2023 | 9 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2013 | 790 | 0.240 |
Why?
|
| Carotid Artery Diseases | 2 | 2018 | 22 | 0.240 |
Why?
|
| Aorta | 3 | 2014 | 161 | 0.230 |
Why?
|
| Students, Pharmacy | 1 | 2024 | 37 | 0.230 |
Why?
|
| Health Behavior | 3 | 2014 | 491 | 0.230 |
Why?
|
| Cholecalciferol | 2 | 2013 | 19 | 0.230 |
Why?
|
| Overweight | 3 | 2014 | 233 | 0.230 |
Why?
|
| Socioeconomic Factors | 4 | 2013 | 1003 | 0.220 |
Why?
|
| Apolipoprotein E2 | 1 | 2022 | 6 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2014 | 180 | 0.220 |
Why?
|
| Learning | 1 | 2023 | 108 | 0.210 |
Why?
|
| Chronic Disease | 4 | 2014 | 469 | 0.210 |
Why?
|
| Phospholipids | 1 | 2022 | 68 | 0.210 |
Why?
|
| Pacific Islands | 1 | 2022 | 115 | 0.210 |
Why?
|
| Medical Audit | 2 | 2012 | 24 | 0.210 |
Why?
|
| Caenorhabditis elegans | 1 | 2022 | 74 | 0.210 |
Why?
|
| Program Evaluation | 2 | 2013 | 316 | 0.210 |
Why?
|
| Receptors, Somatotropin | 1 | 2021 | 12 | 0.200 |
Why?
|
| Qualitative Research | 2 | 2020 | 393 | 0.200 |
Why?
|
| Eating | 2 | 2021 | 152 | 0.200 |
Why?
|
| Insulin Resistance | 3 | 2019 | 177 | 0.200 |
Why?
|
| Hormone Replacement Therapy | 2 | 2020 | 41 | 0.200 |
Why?
|
| Interpersonal Relations | 2 | 2017 | 198 | 0.200 |
Why?
|
| Hip Fractures | 2 | 2019 | 26 | 0.200 |
Why?
|
| Mental Status Schedule | 5 | 2016 | 14 | 0.190 |
Why?
|
| Obesity, Abdominal | 2 | 2018 | 26 | 0.190 |
Why?
|
| Proteomics | 1 | 2023 | 302 | 0.190 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2014 | 23 | 0.190 |
Why?
|
| Hearing Loss | 1 | 2020 | 11 | 0.190 |
Why?
|
| Autopsy | 7 | 2019 | 40 | 0.190 |
Why?
|
| Body Composition | 3 | 2017 | 146 | 0.190 |
Why?
|
| Emigrants and Immigrants | 2 | 2020 | 125 | 0.190 |
Why?
|
| Walking | 4 | 2010 | 64 | 0.180 |
Why?
|
| Constipation | 3 | 2009 | 5 | 0.180 |
Why?
|
| Carbonated Beverages | 1 | 2019 | 21 | 0.180 |
Why?
|
| Waist Circumference | 2 | 2017 | 82 | 0.180 |
Why?
|
| Adiponectin | 2 | 2012 | 52 | 0.180 |
Why?
|
| Prognosis | 5 | 2015 | 707 | 0.180 |
Why?
|
| Neuroglia | 1 | 2020 | 117 | 0.180 |
Why?
|
| Frail Elderly | 2 | 2012 | 15 | 0.180 |
Why?
|
| Family Characteristics | 1 | 2020 | 102 | 0.180 |
Why?
|
| Arteries | 2 | 2014 | 67 | 0.180 |
Why?
|
| Bone Density | 1 | 2019 | 76 | 0.170 |
Why?
|
| Multilingualism | 2 | 2010 | 31 | 0.170 |
Why?
|
| Forecasting | 2 | 2014 | 124 | 0.170 |
Why?
|
| Heptachlor Epoxide | 1 | 2018 | 1 | 0.170 |
Why?
|
| Veterans | 3 | 2016 | 115 | 0.170 |
Why?
|
| Regression Analysis | 5 | 2012 | 429 | 0.170 |
Why?
|
| Apolipoprotein E4 | 4 | 2022 | 47 | 0.170 |
Why?
|
| Social Support | 2 | 2013 | 356 | 0.170 |
Why?
|
| Neurons | 3 | 2015 | 1130 | 0.170 |
Why?
|
| Chi-Square Distribution | 5 | 2014 | 213 | 0.170 |
Why?
|
| Group Processes | 1 | 2018 | 21 | 0.170 |
Why?
|
| Referral and Consultation | 2 | 2016 | 110 | 0.170 |
Why?
|
| Language | 2 | 2010 | 143 | 0.170 |
Why?
|
| Abdominal Fat | 1 | 2018 | 21 | 0.170 |
Why?
|
| Cholesterol, LDL | 4 | 2021 | 63 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 198 | 0.160 |
Why?
|
| Pennsylvania | 5 | 2017 | 41 | 0.160 |
Why?
|
| Antidepressive Agents | 2 | 2022 | 53 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2017 | 18 | 0.160 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2017 | 18 | 0.160 |
Why?
|
| Confidence Intervals | 7 | 2015 | 151 | 0.160 |
Why?
|
| Olfaction Disorders | 2 | 2008 | 8 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2012 | 231 | 0.150 |
Why?
|
| Population | 1 | 2016 | 7 | 0.150 |
Why?
|
| Hyperthyroidism | 1 | 2016 | 5 | 0.150 |
Why?
|
| Age of Onset | 2 | 2015 | 98 | 0.150 |
Why?
|
| Hypothyroidism | 1 | 2016 | 18 | 0.150 |
Why?
|
| C-Reactive Protein | 4 | 2015 | 147 | 0.150 |
Why?
|
| Polysomnography | 2 | 2014 | 30 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2016 | 57 | 0.140 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2007 | 13 | 0.140 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2013 | 50 | 0.140 |
Why?
|
| Milk | 1 | 2015 | 48 | 0.140 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2015 | 5 | 0.140 |
Why?
|
| Diet Surveys | 3 | 2012 | 96 | 0.140 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 257 | 0.130 |
Why?
|
| Length of Stay | 1 | 2016 | 184 | 0.130 |
Why?
|
| Menopause | 1 | 2015 | 54 | 0.130 |
Why?
|
| Phenotype | 5 | 2020 | 650 | 0.130 |
Why?
|
| Gene Frequency | 4 | 2018 | 155 | 0.130 |
Why?
|
| Hospital Mortality | 1 | 2016 | 183 | 0.130 |
Why?
|
| Insulin | 2 | 2014 | 224 | 0.130 |
Why?
|
| Genetic Association Studies | 3 | 2021 | 102 | 0.130 |
Why?
|
| Vitamins | 1 | 2015 | 91 | 0.130 |
Why?
|
| Hemoglobins | 2 | 2015 | 101 | 0.130 |
Why?
|
| Psychometrics | 3 | 2011 | 292 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2021 | 322 | 0.120 |
Why?
|
| Checklist | 1 | 2014 | 10 | 0.120 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 21 | 0.120 |
Why?
|
| Mobility Limitation | 1 | 2014 | 12 | 0.120 |
Why?
|
| Environment | 2 | 2018 | 130 | 0.120 |
Why?
|
| Monitoring, Ambulatory | 1 | 2013 | 13 | 0.120 |
Why?
|
| Body Height | 1 | 2014 | 52 | 0.120 |
Why?
|
| Severity of Illness Index | 6 | 2015 | 608 | 0.120 |
Why?
|
| Palau | 1 | 2013 | 7 | 0.120 |
Why?
|
| Hand Strength | 2 | 2011 | 21 | 0.120 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2013 | 1 | 0.120 |
Why?
|
| Interviews as Topic | 2 | 2012 | 356 | 0.120 |
Why?
|
| Primary Prevention | 2 | 2012 | 57 | 0.120 |
Why?
|
| Energy Intake | 3 | 2015 | 160 | 0.120 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2013 | 28 | 0.120 |
Why?
|
| Prions | 1 | 2013 | 25 | 0.120 |
Why?
|
| Nutritional Status | 3 | 2012 | 114 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2013 | 468 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2012 | 528 | 0.110 |
Why?
|
| Depressive Disorder | 2 | 2006 | 166 | 0.110 |
Why?
|
| Nutrition Disorders | 1 | 2012 | 12 | 0.110 |
Why?
|
| Cost Control | 1 | 2012 | 8 | 0.110 |
Why?
|
| Aortography | 3 | 2019 | 10 | 0.110 |
Why?
|
| Coffee | 2 | 2011 | 20 | 0.110 |
Why?
|
| Education, Nursing, Continuing | 1 | 2012 | 11 | 0.110 |
Why?
|
| Fatty Liver | 1 | 2013 | 56 | 0.110 |
Why?
|
| Thromboembolism | 1 | 2012 | 14 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 165 | 0.110 |
Why?
|
| Health Services Misuse | 1 | 2012 | 12 | 0.110 |
Why?
|
| Drug Utilization | 1 | 2012 | 29 | 0.110 |
Why?
|
| Open Reading Frames | 1 | 2012 | 73 | 0.110 |
Why?
|
| Program Development | 1 | 2013 | 225 | 0.110 |
Why?
|
| Attitude to Health | 2 | 2011 | 311 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2014 | 287 | 0.100 |
Why?
|
| Models, Anatomic | 1 | 2011 | 22 | 0.100 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 11 | 0.100 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2011 | 22 | 0.100 |
Why?
|
| Fractures, Bone | 1 | 2011 | 51 | 0.100 |
Why?
|
| Systole | 4 | 2017 | 65 | 0.100 |
Why?
|
| Ankle Brachial Index | 3 | 2016 | 16 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2023 | 19 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2012 | 131 | 0.100 |
Why?
|
| Geriatric Nursing | 1 | 2010 | 4 | 0.100 |
Why?
|
| Teaching | 1 | 2011 | 51 | 0.100 |
Why?
|
| Caffeine | 1 | 2011 | 26 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2013 | 628 | 0.100 |
Why?
|
| Heat-Shock Proteins | 2 | 2023 | 51 | 0.090 |
Why?
|
| Models, Neurological | 1 | 2011 | 123 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 55 | 0.090 |
Why?
|
| Hospices | 1 | 2010 | 3 | 0.090 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 2 | 2021 | 13 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2010 | 37 | 0.090 |
Why?
|
| Memory Disorders | 1 | 2010 | 65 | 0.090 |
Why?
|
| Solvents | 1 | 2010 | 93 | 0.090 |
Why?
|
| Health Surveys | 1 | 2011 | 358 | 0.090 |
Why?
|
| Writing | 1 | 2009 | 33 | 0.090 |
Why?
|
| Metals | 1 | 2010 | 95 | 0.090 |
Why?
|
| Ethics Consultation | 1 | 2008 | 3 | 0.090 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2008 | 4 | 0.090 |
Why?
|
| Aptitude | 1 | 2008 | 4 | 0.090 |
Why?
|
| Arthritis | 1 | 2009 | 16 | 0.090 |
Why?
|
| Residence Characteristics | 2 | 2009 | 301 | 0.090 |
Why?
|
| Age Distribution | 4 | 2012 | 223 | 0.090 |
Why?
|
| Carotid Stenosis | 1 | 2008 | 13 | 0.080 |
Why?
|
| Fatty Acids | 2 | 2022 | 118 | 0.080 |
Why?
|
| Cross-Cultural Comparison | 1 | 2008 | 100 | 0.080 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 16 | 0.080 |
Why?
|
| Psychomotor Performance | 2 | 2006 | 126 | 0.080 |
Why?
|
| Coronary Stenosis | 1 | 2008 | 36 | 0.080 |
Why?
|
| Patient Care | 1 | 2008 | 28 | 0.080 |
Why?
|
| Cerebral Infarction | 2 | 2005 | 17 | 0.080 |
Why?
|
| Thyroid Diseases | 1 | 2007 | 4 | 0.080 |
Why?
|
| Thyroid Gland | 1 | 2007 | 17 | 0.080 |
Why?
|
| Problem-Based Learning | 1 | 2008 | 32 | 0.080 |
Why?
|
| Gynecology | 1 | 2007 | 31 | 0.080 |
Why?
|
| Demography | 1 | 2008 | 167 | 0.080 |
Why?
|
| Haplotypes | 2 | 2018 | 152 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2015 | 233 | 0.080 |
Why?
|
| Neocortex | 1 | 2007 | 26 | 0.080 |
Why?
|
| Obstetrics | 1 | 2007 | 38 | 0.080 |
Why?
|
| Risk | 5 | 2005 | 256 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2007 | 7 | 0.080 |
Why?
|
| Mass Screening | 3 | 2008 | 427 | 0.080 |
Why?
|
| Depressive Disorder, Major | 1 | 2008 | 102 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 271 | 0.080 |
Why?
|
| Intracranial Embolism | 2 | 2004 | 2 | 0.070 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2006 | 4 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2007 | 49 | 0.070 |
Why?
|
| Vitamin B Complex | 1 | 2006 | 5 | 0.070 |
Why?
|
| Glucose Intolerance | 1 | 2007 | 42 | 0.070 |
Why?
|
| Vitamin B 12 | 1 | 2006 | 19 | 0.070 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 5 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2006 | 41 | 0.070 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2006 | 16 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2006 | 73 | 0.070 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2006 | 50 | 0.070 |
Why?
|
| Physicians | 1 | 2008 | 148 | 0.070 |
Why?
|
| Decision Making | 1 | 2008 | 189 | 0.070 |
Why?
|
| Disabled Persons | 1 | 2006 | 60 | 0.070 |
Why?
|
| Physical Fitness | 1 | 2006 | 78 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 141 | 0.070 |
Why?
|
| Brain Infarction | 2 | 2016 | 20 | 0.070 |
Why?
|
| Estrogens | 1 | 2006 | 190 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2004 | 36 | 0.060 |
Why?
|
| Social Behavior | 1 | 2006 | 124 | 0.060 |
Why?
|
| Probability | 3 | 2010 | 75 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2013 | 1802 | 0.060 |
Why?
|
| Parkinsonian Disorders | 1 | 2004 | 35 | 0.060 |
Why?
|
| Feeding Behavior | 2 | 2008 | 418 | 0.060 |
Why?
|
| Triglycerides | 2 | 2015 | 129 | 0.060 |
Why?
|
| Magnesium Deficiency | 1 | 2003 | 2 | 0.060 |
Why?
|
| Tetanus | 1 | 2003 | 3 | 0.060 |
Why?
|
| Reference Values | 3 | 2014 | 204 | 0.060 |
Why?
|
| Thinness | 2 | 2014 | 29 | 0.060 |
Why?
|
| Young Adult | 1 | 2013 | 4012 | 0.060 |
Why?
|
| Memory | 1 | 2005 | 165 | 0.060 |
Why?
|
| Survival Rate | 2 | 2016 | 310 | 0.060 |
Why?
|
| Students, Medical | 1 | 2005 | 121 | 0.060 |
Why?
|
| Animals | 4 | 2022 | 14307 | 0.060 |
Why?
|
| Magnesium | 1 | 2003 | 95 | 0.060 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 63 | 0.060 |
Why?
|
| Microcirculation | 1 | 2002 | 39 | 0.060 |
Why?
|
| Blood Glucose | 2 | 2021 | 333 | 0.060 |
Why?
|
| Hormones | 1 | 2022 | 51 | 0.060 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2002 | 1 | 0.050 |
Why?
|
| Education, Medical | 2 | 2018 | 97 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2002 | 71 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2022 | 61 | 0.050 |
Why?
|
| Nutrition Assessment | 2 | 2013 | 77 | 0.050 |
Why?
|
| Diabetic Angiopathies | 1 | 2002 | 20 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 157 | 0.050 |
Why?
|
| Automobile Driving | 1 | 2002 | 27 | 0.050 |
Why?
|
| Postmortem Changes | 3 | 2007 | 19 | 0.050 |
Why?
|
| Brain Diseases | 1 | 2002 | 33 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 555 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 901 | 0.050 |
Why?
|
| Linear Models | 2 | 2012 | 253 | 0.050 |
Why?
|
| Brachial Artery | 2 | 2014 | 31 | 0.050 |
Why?
|
| Antioxidants | 1 | 2004 | 386 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2012 | 212 | 0.050 |
Why?
|
| Pattern Recognition, Automated | 1 | 2020 | 30 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 63 | 0.050 |
Why?
|
| Diabetes Complications | 2 | 2016 | 91 | 0.050 |
Why?
|
| Micronesia | 1 | 2020 | 87 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 125 | 0.050 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2019 | 7 | 0.050 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2019 | 21 | 0.050 |
Why?
|
| alpha-Synuclein | 1 | 2019 | 48 | 0.040 |
Why?
|
| Calcium | 2 | 2015 | 445 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 307 | 0.040 |
Why?
|
| Sirtuins | 1 | 2018 | 12 | 0.040 |
Why?
|
| Heart Rate | 1 | 2020 | 248 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 75 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2018 | 58 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2012 | 269 | 0.040 |
Why?
|
| International Cooperation | 1 | 2018 | 44 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2008 | 111 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2018 | 39 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 336 | 0.040 |
Why?
|
| Inflammation | 1 | 2002 | 577 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2011 | 171 | 0.040 |
Why?
|
| Early Diagnosis | 2 | 2008 | 62 | 0.040 |
Why?
|
| Laminin | 1 | 2017 | 59 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 301 | 0.040 |
Why?
|
| Diastole | 1 | 2017 | 46 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 69 | 0.040 |
Why?
|
| Genome, Human | 1 | 2017 | 112 | 0.040 |
Why?
|
| Cell Count | 2 | 2009 | 129 | 0.040 |
Why?
|
| Morbidity | 1 | 2016 | 94 | 0.040 |
Why?
|
| Chromatin | 1 | 2017 | 164 | 0.040 |
Why?
|
| Heterozygote | 1 | 2016 | 91 | 0.040 |
Why?
|
| Sweden | 1 | 2015 | 12 | 0.030 |
Why?
|
| France | 1 | 2015 | 17 | 0.030 |
Why?
|
| Binding Sites | 1 | 2017 | 597 | 0.030 |
Why?
|
| Spain | 1 | 2015 | 33 | 0.030 |
Why?
|
| Hot Flashes | 1 | 2015 | 7 | 0.030 |
Why?
|
| Dietary Carbohydrates | 1 | 2015 | 30 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2015 | 18 | 0.030 |
Why?
|
| Dietary Proteins | 1 | 2015 | 30 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2015 | 34 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 76 | 0.030 |
Why?
|
| Base Sequence | 1 | 2017 | 932 | 0.030 |
Why?
|
| Uric Acid | 1 | 2015 | 26 | 0.030 |
Why?
|
| Canada | 1 | 2015 | 121 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2006 | 106 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 91 | 0.030 |
Why?
|
| Fatigue | 1 | 2015 | 79 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2015 | 115 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 913 | 0.030 |
Why?
|
| Manometry | 1 | 2014 | 7 | 0.030 |
Why?
|
| Plethysmography | 1 | 2014 | 7 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2014 | 11 | 0.030 |
Why?
|
| Fasting | 1 | 2014 | 50 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 288 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 325 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2014 | 29 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 114 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2013 | 2 | 0.030 |
Why?
|
| Genes, jun | 1 | 2013 | 7 | 0.030 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Genes, p16 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2017 | 486 | 0.030 |
Why?
|
| Exodeoxyribonucleases | 1 | 2013 | 14 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 20 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2013 | 38 | 0.030 |
Why?
|
| Exercise | 1 | 2018 | 524 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 66 | 0.030 |
Why?
|
| Organ Size | 1 | 2013 | 148 | 0.030 |
Why?
|
| Emotions | 1 | 2015 | 204 | 0.030 |
Why?
|
| Iceland | 1 | 2012 | 5 | 0.030 |
Why?
|
| Spleen | 1 | 2013 | 192 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 211 | 0.030 |
Why?
|
| Compliance | 1 | 2012 | 9 | 0.030 |
Why?
|
| Pulsatile Flow | 1 | 2012 | 15 | 0.030 |
Why?
|
| Seafood | 1 | 2012 | 19 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 31 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 159 | 0.030 |
Why?
|
| Linoleic Acid | 1 | 2011 | 7 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2011 | 32 | 0.030 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2011 | 6 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 92 | 0.020 |
Why?
|
| Hemosiderosis | 1 | 2010 | 1 | 0.020 |
Why?
|
| Language Tests | 1 | 2010 | 8 | 0.020 |
Why?
|
| Tea | 1 | 2011 | 41 | 0.020 |
Why?
|
| Speech | 1 | 2010 | 11 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 420 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 447 | 0.020 |
Why?
|
| Men's Health | 1 | 2010 | 9 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 2010 | 101 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 37 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 64 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 92 | 0.020 |
Why?
|
| Aspirin | 1 | 2010 | 45 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 5035 | 0.020 |
Why?
|
| Diagnosis | 1 | 2009 | 8 | 0.020 |
Why?
|
| Locus Coeruleus | 1 | 2009 | 15 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 347 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 77 | 0.020 |
Why?
|
| Defensive Medicine | 1 | 2008 | 1 | 0.020 |
Why?
|
| Advance Directive Adherence | 1 | 2008 | 1 | 0.020 |
Why?
|
| Tunica Media | 1 | 2008 | 14 | 0.020 |
Why?
|
| Medical Futility | 1 | 2008 | 8 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2008 | 21 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2008 | 19 | 0.020 |
Why?
|
| Professional Practice Location | 1 | 2008 | 14 | 0.020 |
Why?
|
| Health | 1 | 2008 | 28 | 0.020 |
Why?
|
| Specialization | 1 | 2008 | 21 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 89 | 0.020 |
Why?
|
| Olfactory Pathways | 1 | 2008 | 14 | 0.020 |
Why?
|
| Ankle Joint | 1 | 2007 | 2 | 0.020 |
Why?
|
| Pick Disease of the Brain | 1 | 2007 | 4 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 642 | 0.020 |
Why?
|
| Medicine | 1 | 2008 | 31 | 0.020 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2007 | 12 | 0.020 |
Why?
|
| Thyroxine | 1 | 2007 | 17 | 0.020 |
Why?
|
| Smell | 1 | 2008 | 35 | 0.020 |
Why?
|
| Urban Population | 1 | 2010 | 318 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 75 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2007 | 23 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 435 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2007 | 51 | 0.020 |
Why?
|
| Cuba | 1 | 2006 | 32 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2007 | 55 | 0.020 |
Why?
|
| Gels | 1 | 2006 | 41 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2006 | 77 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2008 | 173 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2007 | 118 | 0.020 |
Why?
|
| Community Health Planning | 1 | 2006 | 35 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2006 | 16 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2006 | 32 | 0.020 |
Why?
|
| Postural Balance | 1 | 2006 | 29 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2006 | 38 | 0.020 |
Why?
|
| Public Health | 1 | 2010 | 348 | 0.020 |
Why?
|
| Pulse | 1 | 2005 | 10 | 0.020 |
Why?
|
| Exercise Test | 1 | 2006 | 68 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 1349 | 0.020 |
Why?
|
| Weight Gain | 1 | 2007 | 128 | 0.020 |
Why?
|
| Registries | 1 | 2007 | 330 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 111 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2006 | 202 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2006 | 243 | 0.020 |
Why?
|
| Physical Examination | 1 | 2005 | 40 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2008 | 562 | 0.020 |
Why?
|
| Body Weight | 1 | 2007 | 404 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2005 | 94 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 54 | 0.020 |
Why?
|
| beta Carotene | 1 | 2004 | 11 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2004 | 100 | 0.020 |
Why?
|
| Health Promotion | 1 | 2010 | 588 | 0.020 |
Why?
|
| Ascorbic Acid | 1 | 2004 | 63 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2004 | 65 | 0.020 |
Why?
|
| Vitamin E | 1 | 2004 | 56 | 0.020 |
Why?
|
| Flavonoids | 1 | 2004 | 78 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2003 | 25 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2006 | 283 | 0.010 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2002 | 1 | 0.010 |
Why?
|
| Parotid Neoplasms | 1 | 2002 | 3 | 0.010 |
Why?
|
| World Health Organization | 1 | 2002 | 30 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 105 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2002 | 62 | 0.010 |
Why?
|
| Cerebral Ventricles | 1 | 2002 | 23 | 0.010 |
Why?
|
| Atrophy | 1 | 2002 | 40 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 2003 | 207 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 211 | 0.010 |
Why?
|